Clinical Trial Update: Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab plus doxorubicin in advanced, recurrent, or metastatic endometrial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Neoplasms

Drugs mentioned

• Doxorubicin (doxorubicin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Vall d'Hebron Institute of Oncology | Conditions: Endometrial Neoplasms | Phase 2 | Status: COMPLETED